Paroxysmal Supraventricular Tachycardia: A Century of Progress

McGuire, Mark A.

doi:10.1016/j.hlc.2007.02.107

Cited by 7 publications

(3 citation statements)

References 59 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Early reports on the use of ATP in the acute management of PSVT clearly indicate that the users were not familiar with the mechanism that mediated its beneficial effect. The most common mechanisms of PSVT were only proposed in the mid 1960s based on experimental studies and confirmed subsequently in the clinical setting in the early 1970s [16,17].…”

Section: Atp As An Anti-arrhythmic Drugmentioning

confidence: 98%

ATPace™: injectable adenosine 5′-triphosphate

Pelleg

Kutalek

Flammang

et al. 2011

Purinergic Signalling

View full text Add to dashboard Cite

ATPace™, a novel injectable formulation of adenosine 5′-triphosphate (ATP), is developed by Cordex Pharma, Inc. (Cordex) as a diagnostic and therapeutic drug for the management of cardiac bradyarrhythmias. Extracellular ATP exerts multiple effects in various cell types by activating cell-surface receptors known as P2 receptors. In the heart, ATP suppresses the automaticity of cardiac pacemakers and atrioventricular (AV) nodal conduction via adenosine, the product of its degradation by ecto-enzymes, as well as by triggering a cardiocardiac vagal reflex. ATP, given as a rapid intravenous bolus injection, has been used since the late 1940s as a highly effective and safe therapeutic agent for the acute termination of reentrant paroxysmal supraventricular tachycardia (PSVT) involving the AV node. In addition, preliminary studies have shown that ATP can also be used as a diagnostic agent for the identification of several cardiac disorders including sinus node dysfunction (sick sinus syndrome), dual AV nodal pathways, long QT syndrome, and bradycardic syncope. The US Food and Drug Administration has approved Cordex formulation for ATP as an Investigational New Drug and two pathways for its marketing approval; one therapeutic, i.e., acute termination of paroxysmal PSVT, and the other diagnostic, i.e., the identification of patients with bradycardic syncope who can benefit from pacemaker therapy. The scientific rationale for the development of ATPace™ is discussed.

show abstract

Section: Atp As An Anti-arrhythmic Drugmentioning

confidence: 98%

ATPace™: injectable adenosine 5′-triphosphate

Pelleg

Kutalek

Flammang

et al. 2011

Purinergic Signalling

View full text Add to dashboard Cite

show abstract

“…Therapies to revert supraventricular tachycardia (SVT) to sinus rhythm have included vagal manoeuvres, pharmacological agents (e.g. verapamil) and specific therapeutic interventions linked to patient perfusion . The use of synchronised cardioversion has been reserved for those patients with poor perfusion, or who are rapidly deteriorating .…”

Section: Introductionmentioning

confidence: 99%

“…verapamil) and specific therapeutic interventions linked to patient perfusion. [1][2][3][4][5] The use of synchronised cardioversion has been reserved for those patients with poor perfusion, or who are rapidly deteriorating. [6][7][8][9][10] In the 1990s, EMS providers examined adenosine as an alternative to verapamil as the primary pharmacological agent, with many adopting this new drug.…”

Section: Introductionmentioning

confidence: 99%